Thank you for submitting your manuscript on mitotic checkpoint/apoptosis crosstalk for our editorial consideration. We have now received the comments of three expert referees, copied below for your information. As you will see, the referees acknowledge the importance of the topic and consider several of your findings potentially interesting. However, they also criticize that some other findings such as p31 roles in adaptation have already been previously established, and that there are currently rather superficial insights into the underlying mechanisms, especially with regard to the more novel and surprising observations. Given these critical opinions especially from referees 1 and 3, I am afraid we are not convinced that this manuscript is at the present stage well suited for publication in The EMBO Journal. At the same time, I disagree with referee 3's sentiment that each lead should be followed up in a separate future study, and instead feel that the study could become a much more compelling candidate if further insights into some of the main open questions could be obtained and added -especially into the nature of the apparent p31 cell death roles, and of the mitotic timing roles of cell death regulators. Likewise, it would be essential to validate Noxa as key mitotic death regulator in additional cellular systems. Finally, I feel that the resource value of your RNAi screen would be increased by some further computational analysis, as well as by moving Figure S1 into the main article (as Figure 1) and adding considerably more discussion on these data (generally, the discussion section appears at present much to short to appropriately put the study's main results into context). In addition to these general concerns, the reviewers also bring up a number of more specific issues (such as further controls) that would need to be addressed.
Since adequate improvement would in this case go beyond regular revisions and require major extensions of the study, I hope you understand that I am presently not able to make strong commitments regarding eventual publication of this work, and that the final decision would have to depend on convincing the critical referees with new data and diligent responses. Should you nevertheless decide to revise the manuscript for The EMBO Journal, please use the link below to resubmit a revised version and response letter within the indicated period -we would in this case be open to discussing an extension of the resubmission deadline up to a total of six months if needed. As always, it is our policy that competing manuscripts published during this period will have no negative impact on our final assessment of your revised study.
Thank you again for the opportunity to consider this work for publication, and please do not hesitate to contact me in case you should have any additional question regarding this decision or the reports. I look forward to your revision.
_____ REFEREE REPORTS:
Referee #1:
Starting off from the genome wide siRNA screen the authors identify components of mitotic adaptation/slippage and apoptosis pathways. In a secondary screen about 40 targets of the initial screen were confirmed to modulate survival of Taxol treated Hela cells. Two candidates, the Mad2 inhibitor p31 comet and the BH3-only protein Noxa were investigated further in this processes because of their known roles in check-point signaling and cell death, respectively.
In subsequent analysis the authors interrogate 3 different biological phenomena: 1. The role of p31comet in a) adaptation and b) mitotic survival 2. The role of Noxa in mitotic cell death 3. The role of Noxa and Bax/Bak in adaptation Novelty of the initial part of the findings is clearly limited. Work by several groups has defined a role for p31comet in adaptation previously (Ma et al, 2012; Mansfeld et al, 2011; Varetti et al, 2011) . The value of the work here resides in the fact that p31comet stands out in the genome wide screen, arguing that -at least under these experimental conditions -p31comet and the APC/C are among the most relevant factors contributing to the live/death decision upon mitotic arrest. Somewhat surprisingly, Cdc20, a key component of the APC/C proteolysis pathway initiating mitotic exit and clearly required for adaptation was not a hit in the RNAi screen.
The authors show then that the pro-survival role p31comet in mitotic arrest is not only exerted via its ability to promote adaptation, but appears somehow more direct. This conclusion is drawn based on the comparison of Cdc20 depletion with p31comet depletion. Both are able to suppress adaptation, but the depletion of p31comet accelerates cell death in addition. As p31comet depletion is known to elevate Cdc20 levels it is rather crucial to exclude that the apoptotic acceleration observed upon p31comet siRNA depends on a Cdc20 gain of function. Additionally, differences in time to death in mitosis upon p31 or Cdc20 KD may be related to different knock-down efficiencies of the relevant targets. KD efficiencies are never compared by Western analysis and this control is missing in Fig.  2E . Cdc20 gain of function effects seems to be excluded by the fact that p31 and Cdc20 double depletion shows a "p31-like" phenotype. Still, it would be crucial here to show by Western blot the levels of Cdc20 and p31comet in mitotic extracts upon single and double depletion. More importantly, there is no description of any possible mechanism on how p31 comet might do this job. As pinpointed by the authors, Mcl1 degradation in mitosis is one of the best-characterized apoptotic events during mitotic arrest. In Figure 2D it seems that upon p31comet depletion Mcl-1 becomes degraded more rapidly.Is this phenomenon reproducible, if so it may well be an important hint for a possible mechanism. As Cdc20 depletion reportedly impacts on Mcl1 degradation, it would be meaningful to compare the mitotic decay of Mcl1 in control cells, Cdc20, p31comet and double depleted cells. Based on the concept presented later, one would predict to see differences in Noxa expression/accumulation. Hence, reprobing the Western in Fig. 2D might shed some light. In fact, it would be a nice linking figure to the data presented in Fig. 3 .
To circumstantiate the notion that p31comet triggers adaptation by promoting Cyclin B1 degradation, the authors follow the levels of Cyclin B1 and the underlying CDK1 activity during mitotic arrest (Figure 1) , showing that CHX treatment accelerates CyclinB1 degradation and therefore adaptation, whereas p31comet depletion can revert such acceleration. A very similar set of experiments has been already performed in a paper by the Musacchio group in Molecular Cell (Varetti et al, 2011) and although the different readouts used here bring in some additional characterization of the phenomenon, it would be fair to cite the original contribution. In addition, although it is likely that cells showing an almost 4C DNA content and MPM2 levels inferior to those observed in interphase are apoptotic (as argued by the authors), it would be important that the authors really provide evidence for this notion. As a suitable marker for the flow cytometry analysis, cleaved caspase-3 should be used.
In the discussion the sentence "Therefore, it is surprising that p31comet is required for adaptation in taxol, suggesting that the basal APC/C activity observed during mitotic arrest is produced by p31comet-dependent inactivation of Mad2 and that low levels of inactivation occur even in the presence of an active checkpoint" neglects not only the above mentioned Musacchio paper but also two other papers, all of them solidly showing a role for p31comet in adaptation (Ma et al, 2012; Mansfeld et al, 2011; Varetti et al, 2011) .
In relation to part two, the role of Noxa in mitotic death, it seems critical to this referee to show Noxa and Mcl1 protein levels in asynchronous vs. early/late arrested cells in Hela and U2OS cells, as there should also be a difference in the Mcl1/Noxa ratio that might reflect the different behavior of these cells upon Taxol treatment. Key experiments (e.g. Fig. 3H ) are only performed with one siRNA and although mentioned in the text that "similar findings were made using a different siRNA targeting Noxa", this data should be shown.
It also remains to be discussed that Noxa null mutant mice show no prominent cell death phenotype, suggesting that it can be well compensated for by other BH3-only proteins in vivo. Along this line, Bim has been implicated by others to contribute to Taxol-mediated cell death (e.g. Kutuk & Letai, CDD 2010 ), yet this has not been linked directly to extended mitotic arrest. However, CDK1 dependent phosphorylation of Bim appears to target it for degradation in mitosis (Teodoro, CDD, 2013) . Hence, a drop in CDK1 activity could stablize Bim and contribute to killing. This could be discussed.
In relation to part three, the role of Bcl2 family proteins in adaptation, it seems important to point out that the evidence supports indeed the notion that the Noxa-Bax/Bak mitochondrial module plays a role in promoting adaptation independently of its apoptotic function. This is clearly in contrast to the competing network hypothesis by Taylor and colleagues who propose that independent molecular circuits are at work and depletion of Bax/Bak should have no impact on mitotic timing. I think these observations are highly interesting. The main issue here is that there is no kind of mechanistic understanding of how this should happen. As above, it would be of interest to define the role of Mcl-1 degradation in this process. As Mcl-1 overexpression prevents adaptation by suppressing death in HeLa it may be worthwhile to probe for Mcl1 levels after Bax/Bak or Noxa depletion. More interesting, however, would be the approach to overexpress Mcl1 in U2OS cells and see if adaptation becomes slower, as shown for Noxa or Bax Bak depletion. However, this still would not provide a mechanism.
A general notion, the authors frequently quantify apoptosis after depletion of Bax/Bak or in the presence of caspase inhibitors. As we have to assume that the cell death observed under these conditions may no longer be apoptotic, a more neutral description would seem appropriate, i.e. cell death. In this manuscript, Diaz-Martinez et al. investigate the molecular pathways regulating cellular responses to prolonged activation of the spindle checkpoint. It is well established that sustained exposure to microtubule poisons can lead to mitotic cell death, a putative mechanism by which some cancer therapeutics may specifically target proliferating cells. However, cells can also exit mitosis alive during sustained spindle checkpoint activation, which is mediated by a low residual activity of the anaphase promoting complex, and may contribute to the development of resistance to cancer therapeutics. Whether cells predominantly die in mitosis or exit by mitotic slippage is highly variable between different cell types and the molecular control governing these cell fate decisions is poorly understood. Previous studies suggest that the relative contribution of two independent pathways, one promoting mitotic slippage versus another leading to accumulation of pro-apoptotic signals, ultimately determine mitotic cell fate. To systematically determine factors that either promote mitotic slippage or mitotic cell death, the authors first perform a genome-wide RNAi screen scoring cell viability after prolonged exposure to taxol. From a list of several hundred candidate genes, they select p31comet, a known regulator of the spindle checkpoint, and Noxa, a known regulator of apoptosis, for further detailed analysis. Interestingly, they find that p31comet depletion induced mitotic cell death significantly faster compared to Cdc20 depletion, indicating that p31comet has a specific function in suppressing mitotic apoptosis signals independent of its known direct control on mitotic duration. The authors further find that Noxa is an important inhibitor of mitotic cell death as part of the intrinsic mitochondrial apoptosis pathway. Unexpectedly, they find that Noxa and the downstream signaling components Bax/Bak not only suppressed mitotic cell death but also prolonged mitotic duration before adaptation/slippage. This indicates an interesting new layer of control by crosstalk between the pro-apoptotic and mitotic slippage regulatory pathways. Even though the molecular mechanisms underlying this cross-talk of regulatory pathways are not determined in this study, these findings will be interesting for a broad readership.
Overall, the experiments are well designed and the data is of high quality. There are a few points, however, that need to be addressed before this study can be published:
Major points Some statements in the main text lack support by data (e.g., p. 11 "...Bim, had no major effects on mitotic cell death in HeLa cells" is stated without reference to Figs.; similarly, p.12 "Similar results were obtained with siNoxa-2" should be supported by quantitative data)
Reference to experimental data is missing on p. 7: "Depletion of p31comet indeed decreased the extent of mitotic adaptation in HeLa cells..." This and the entire following paragraph reports conclusions without reference to data shown in figures.
An indication of experimental variation by error bars should be added to Fig. 3B , C, G, as well as a test for statistical significance The screening assay and data analysis should be better explained in the main text.
Referee #3:
This manuscript describes the results of an siRNA screen looking for factors that regulate apoptosis and mitotic adaptation following taxol-mediated mitotic arrest. This is an interesting area of research, but I find the manuscript frustrating. There is much work and some interesting information in it, but the mechanistic insights are not yet clear and I think it would be premature to publish at present.
The work falls into three main components, the role of p31 comet, the role of Noxa, and contribution of Bax and Bak. Much of the data is consistent with previous work or is confirmatory. For instance the role of p31comet in the mitotic checkpoint, or that Bax/Bak are required for apoptosis in response to taxol. This is fine, but does not provide significant new insights. It is an advance to identify Noxa as being important for mitotic cell death, at least in Hela, but its role may be limited to these cells. Where the manuscript is more progressive, for instance indicating that p31comet somehow affects apoptosis in addition to its role in the checkpoint, we unfortunately have no new mechanistic insights. Similarly, whether Noxa, Bak or Bax affect mitotic controls in addition to roles in apoptosis, as is suggested, then we have no information on the mechanism. I think it would be much better for the authors to fully investigate each of these pieces in more detail in order to understand the meaning of the phenomena that they observe; they might then be published separately.
The data is deficient in some aspects and lacks statistical analysis; it is not clear how many times experiments were conducted and what variability was found, e.g. the analysis of time in mitosis shown in Fig2F, G and subsequent figures. The experiment shown in figure 2E , which shows effects of siRNA treatment for 48hrs of presumably initially asyncronous cells is not well-designed: this needs a mitotic marker such as phosphohistone H3-S10 or MPM2 and is difficult to interpret because each of the three samples is expected to be different in cell cycle stage, with the mock being asynchronous, the siCdc20 being arrested in mitosis and the siP31 being deficient in mitotic cellslevels of Mcl1 in particular are known to be cell cycle regulated. Most importantly no Cdc20 blot is shown to demonstrate any effect of siCdc20. This data is only cited out of sequence at the end of the results section. The siRNA knockdown of cytochrome c (Fig, s6) is not supported by evidence that the protein is indeed depleted and I would find it surprising if such cells were viable. There is also a potential general problem with off target effects of many siRNAs on the mitotic checkpoint, for instance by depleting Mad2 (Sigoillot et al Nature Methods 9(4) 363), leading to spurious results. We are submitting a revised version of the above referenced manuscript now titled "Genome-wide siRNA Screen Reveals Coupling between Mitotic Apoptosis and Adaptation" for publication in EMBO J. I would like to thank you for your valuable editorial suggestions. I am also grateful to the three reviewers for their constructive comments. We have tried our best to address your points and those of the reviewers. As a result, the paper is now greatly improved. Before I go into the details of the revisions, I will summarize the major new findings and additions to the manuscript.
In the original version of the manuscript, we reported two main findings. First, we described a genome-wide siRNA screen for regulators of mitotic cell death. We feel that this is an important resource for the field. As you suggested, we have now added statistical analysis of the functional networks identified in the screen. We have included brief discussions about each network. In addition, we have changed the title to emphasize the siRNA screen, and have simplified the supplementary tables. These modifications have increased the resource values of the paper. We have discussed the prevalent Mad2 off-target effects. We stress that we have limited the Mad2 offtarget effects with a secondary screen using a separate siRNA library. We are confident of the validity of the four functional networks defined in our screen.
The second main finding is that the apoptosis and adaptation pathways during a prolonged mitotic arrest are coupled. We described two such coupling mechanisms: (1) p31 comet regulates both adaptation and apoptosis; and (2) the well-established apoptosis factors Bax/Bak promote adaptation. These findings suggest a new paradigm to explain the heterogeneity of cellular responses to antimitotic anticancer drugs. A major concern of the reviewers was the lack of detailed mechanisms linking p31 comet to apoptosis and Bax/Bak to adaptation. In a separate study in the lab, we have shown that p31 comet regulates growth factor signaling. Its role in suppressing apoptosis is indirectly mediated through this new signal transduction function of p31 comet . That study is almost completed and will be reported in due course. It is impractical to include those mechanistic studies in the current manuscript. I feel strongly, however, that we should report the initial connection between p31 comet and apoptosis in the current study.
On the Bax/Bak front, after many failed attempts, we obtained exciting new results that provided key insights into the mechanism by which Bax/Bak promote adaptation. We had initially focused on the mitochondrial factors that were released into the cytosol during apoptosis in a Bax/Bak-dependent manner, including cytochrome c, Smac, Omi, AIF, and Endo G. Inactivation of none of these factors extended mitotic duration. We thus considered the established connection between Bax/Bak and the mitochondrial fission factor Drp1. Strikingly, depletion of Drp1 with multiple siRNAs, as well as chemical inhibition of Drp1 with Mdivi-1, lengthened mitotic duration in U2OS cells without altering the extent of apoptosis (Figure 7) . Furthermore, inhibition of protein synthesis or ATP production abrogated the mitotic effects of Drp1 or Bax/Bak inactivation. These results, along with our finding that the APC/C activity is not altered in siBax/Bak cells (Figure 6 ), strongly support a model in which Bax/Bak act through Drp1 to suppress protein synthesis, thus reducing cyclin B1 steady-state levels and promoting adaptation.
Although these new insights are admittedly not yet at a level of mechanistic details that you are accustomed to seeing in studies from my lab, they do greatly strength our conclusions in the paper. I want to mention that our siRNA screen was completed in 2008, and our results on the requirement for p31 comet in adaption were initially obtained in 2009. Further mechanistic studies will delay the publication of what I feel is the most important paper from my lab in recent years. Any lengthy delay may again allow publications from others on some of the points in our paper, and diminish the timeliness and importance of our findings.
A detailed point-to-point rebuttal of the reviewers' points follows.
Referee #1:
Starting (Ma et al, 2012; Mansfeld et al, 2011; Varetti et al, 2011) .
Response:
We agree with the reviewer that a role of p31 comet in adaptation has already been established and have included the relevant references in the revision. We wish to point out that our siRNA screen was completed in 2008, and our results on the role of p31 comet in adaptation were obtained in 2009. Due to the inordinate difficulty we encountered in publishing our paper, these results are no longer fresh at this time. Some of the claims of novelty in the original submission were relics from earlier versions of our paper submitted elsewhere. We apologize for not catching these inaccurate claims. Response: We thank the reviewer for pointing out the value of our work. This point has now been mentioned in the revised manuscript. We were also surprised by the fact that Cdc20 was not recovered in our screen. On the other hand, false negatives in large-scale screens are quite common. Some of the Cdc20 siRNAs might have deleterious off-target effects. This point is now discussed in the revised manuscript. Figure 3I ). Consistent with a previous report from the Musacchio group, we observed an elevation of Cdc20 levels with p31 comet depletion alone. Importantly, Cdc20 was still depleted efficiently in cells treated with both si-p31 comet and siCdc20. Of course, we cannot exclude the possibility that a small difference in Cdc20 knockdown efficiencies between the singleand double-depletion conditions accounts for the apparent dominant effects of si-p31comet. These points have now been discussed in the revised manuscript.
More importantly, there is no description of any possible mechanism on how p31 comet might do this job. As pinpointed by the authors, Mcl1 degradation in mitosis is one of the best-characterized apoptotic events during mitotic arrest. In Figure 2D it seems that upon p31comet depletion Mcl-1 becomes degraded more rapidly. Is this phenomenon reproducible, if so it may well be an important hint for a possible mechanism. As Cdc20 depletion reportedly impacts on Mcl1 degradation, it would be meaningful to compare the mitotic decay of Mcl1 in control cells, Cdc20, p31comet and double depleted cells.
Response: We agree with the reviewer that we have not provided a possible mechanism on how p31 comet regulates apoptosis. The small effects of p31 comet depletion on Mcl1 degradation in the original Figure 2D ( Figure 3D in the revised version) are not reproducible. We also tested the effects of depletion of Cdc20, Fbw7, and Mule, several ubiquitin ligases implicated in Mcl1 degradation. Somewhat surprisingly, we did not observe mitotic stabilization of Mcl1 following their depletion, suggesting a complicated mechanism of Mcl1 degradation during mitosis. Thus, we have found no evidence to support a model in which p31 comet blocks APC/C-Cdc20-dependent degradation of Mcl1.
We also failed to detect any physical interactions between p31 comet and apoptotic regulators, including Bax/Bak, Noxa, or Mcl1, either by immunoprecipitation of endogenous proteins in human cells or through in vitro pulldown experiments using purified p31 comet , Mad2, or p31 comet -Mad2 and in vitro translated Bax, Bak, Noxa, or Mcl1. These negative results suggest that the role of p31 comet in suppressing apoptosis is quite indirect. In a separate study by another postdoctoral fellow, we have unexpectedly found that p31 comet regulates growth factor signaling. We believe that the role of p31 comet in apoptosis suppression is related to this new, non-canonical role in signal transduction. The function of p31 comet in signal transduction will be reported in due course. We still wish to include the initial finding of p31 comet in apoptosis suppression in the current manuscript, as it is discovered in the screen. Fig. 2D might shed some light. In fact, it would be a nice linking figure to the data presented in Fig. 3 .
Based on the concept presented later, one would predict to see differences in Noxa expression/accumulation. Hence, reprobing the Western in

Response:
As pointed out by the reviewer, another possible mechanism that could explain apoptosis advancement after p31 comet depletion could be through Noxa stabilization. Unfortunately, we cannot reproducibly detect the endogenous Noxa protein in human cells by Western blotting, perhaps due to its small size (7 kDa) and low steady-state levels. Several experienced postdocs and technicians in my lab have tried different gel systems (glycine vs tricine gels), different membranes, and multiple antibodies. None could reproducibly detect endogenous Noxa, although we can easily detect ectopically expressed Myc-or EGFP-Noxa with several Noxa antibodies. We note that several publications have reported Noxa Western blots with the incorrect molecular weight. We could also detect bands with certain Noxa antibodies, but these bands were not depleted by Noxa siRNA. We thus believe that these signals are non-specific cross-reacting species. Therefore, we cannot address whether p31 comet depletion affects endogenous Noxa levels. Because the Noxa blots were not reproducible, we have removed the Noxa blot contained in the original submission. For whatever it's worth, p31 comet depletion did not affect the levels of ectopically expressed Myc-Noxa. Furthermore, as discussed above, we have a plausible explanation for the role of p31 comet in suppressing apoptosis. (Varetti et al, 2011) and although the different readouts used here bring in some additional characterization of the phenomenon, it would be fair to cite the original contribution.
To circumstantiate the notion that p31comet triggers adaptation by promoting Cyclin B1 degradation, the authors follow the levels of Cyclin B1 and the underlying CDK1 activity during mitotic arrest (Figure 1), showing that CHX treatment accelerates CyclinB1 degradation and therefore adaptation, whereas p31comet depletion can revert such acceleration. A very similar set of experiments has been already performed in a paper by the Musacchio group in Molecular Cell
Response:
We thank the reviewer for pointing out this important omission. We have cited the Varetti et al. study. As pointed by the reviewer, our flow cytometry analysis is a single-cell assay, which complements and extends the previous work that uses immunoblotting of a population of cells.
In addition, although it is likely that cells showing an almost 4C DNA content and MPM2 levels inferior to those observed in interphase are apoptotic (as argued by the authors), it would be important that the authors really provide evidence for this notion. As a suitable marker for the flow cytometry analysis, cleaved caspase-3 should be used.
Response: We thank the reviewer for this suggestion. However, after discussions with our flow cytometry core facility, we realized that three-parameter flow cytometry analysis of cells stained with PI, MPM2, and cleaved caspase-3 is technically difficult at our facility. We have added a discussion of the caveat in the text, and hope that the reviewer will understand our technical limitations of doing this experiment. (Ma et al, 2012; Mansfeld et al, 2011; Varetti et al, 2011) .
In the discussion the sentence "Therefore, it is surprising that p31comet is required for adaptation in taxol, suggesting that the basal APC/C activity observed during mitotic arrest is produced by p31comet-dependent inactivation of Mad2 and that low levels of inactivation occur even in the presence of an active checkpoint" neglects not only the above mentioned Musacchio paper but also two other papers, all of them solidly showing a role for p31comet in adaptation
Response:
We agree with the reviewer, and have changed the discussion and included the references.
In relation to part two, the role of Noxa in mitotic death, it seems critical to this referee to show Noxa and Mcl1 protein levels in asynchronous vs. early/late arrested cells in Hela and U2OS cells, as there should also be a difference in the Mcl1/Noxa ratio that might reflect the different behavior of these cells upon Taxol treatment.
Response: We thank the reviewer for the suggestion. In addition to the Western blots in Figure S3A , showing that Mcl1 levels after Noxa depletion in HeLa cells are unchanged, we have now included Western blots showing Mcl1 levels after transfection with siNoxa, siBax, siBak, and siBaxBak in U2OS ( Figure 5A ). Mcl1 levels do not change after Noxa siRNA, and are slightly decreased after siBax, siBak, and siBaxBak. As explained above, because we cannot reproducibly detect endogenous Noxa, a comparison of the ratios of Mcl1/Noxa is not possible at this time.
Key experiments (e.g. Fig. 3H ) are only performed with one siRNA and although mentioned in the text that "similar findings were made using a different siRNA targeting Noxa", this data should be shown.
Response:
We have now included the time lapse data for siNoxa-2 in Figure S3C and D. Taxol-mediated cell death (e.g. Kutuk & Letai, CDD 2010) , yet this has not been linked directly to extended mitotic arrest. However, CDK1 dependent phosphorylation of Bim appears to target it for degradation in mitosis (Teodoro, CDD, 2013) . Hence, a drop in CDK1 activity could stablize Bim and contribute to killing. This could be discussed.
It also remains to be discussed that Noxa null mutant mice show no prominent cell death phenotype, suggesting that it can be well compensated for by other BH3-only proteins in vivo. Along this line, Bim has been implicated by others to contribute to
Response:
We thank the reviewer for the insightful suggestion. We have now added discussion on these points.
In relation to part three, the role of Bcl2 family proteins in adaptation, it seems important to point out that the evidence supports indeed the notion that the Noxa-Bax/Bak mitochondrial module plays a role in promoting adaptation independently of its apoptotic function. This is clearly in contrast to the competing network hypothesis by Taylor and colleagues who propose that independent molecular circuits are at work and depletion of Bax/Bak should have no impact on mitotic timing. I think these observations are highly interesting. The main issue here is that there is no kind of mechanistic understanding of how this should happen. As above, it would be of interest to define the role of Mcl-1 degradation in this process. As Mcl-1 overexpression prevents adaptation by suppressing death in HeLa it may be worthwhile to probe for Mcl1 levels after Bax/Bak or Noxa depletion. More interesting, however, would be the approach to overexpress Mcl1 in U2OS cells and see if adaptation becomes slower, as shown for Noxa or Bax Bak depletion. However, this still would not provide a mechanism.
Response: We thank the reviewer for pointing out the importance of our findings. We have more clearly described the evidence supporting our main conclusion in the discussion. As suggested by the reviewer, we have tested whether Mcl1 overexpression delays mitotic adaptation. As shown in Figure S4H , transiently overexpressed Myc-Mcl1 did not delay adaptation in U2OS cells. This result is consistent with the fact that siNoxa did not delay mitotic adaptation in these cells ( Figure  S5A ). Thus, other Bcl2 family members likely play a crucial role in Bax/Bak regulation. We have discussed these points more thoroughly in the revised manuscript.
More importantly, as discussed above, we have made significant progress towards understanding the mechanism by which Bax/Bak promote adaptation in U2OS cells. We had initially focused on the mitochondrial factors that were released into the cytosol during apoptosis in a Bax/Bak-dependent manner, including cytochrome C, Smac, Omi, AIF and Endo G. Inactivation of none of these factors extended mitotic duration. We thus considered the established connection between Bax/Bak and the mitochondrial fission factor Drp1. Strikingly, depletion of Drp1 with multiple siRNAs, as well as chemical inhibition of Drp1 with Mdivi-1, lengthened mitotic duration in U2OS cells without altering the extent of apoptosis (Figure 7) . Furthermore, inhibition of protein synthesis or ATP production abrogated the mitotic effects of Drp1 or Bax/Bak inactivation. These results, along with our finding that the APC/C activity is not altered in siBax/Bak cells (Figure 6 ), support a model in which Bax/Bak act through Drp1 to suppress protein synthesis, thus reducing cyclin B1 steady-state levels and promoting adaptation.
A general notion, the authors frequently quantify apoptosis after depletion of Bax/Bak or in the presence of caspase inhibitors. As we have to assume that the cell death observed under these conditions may no longer be apoptotic, a more neutral description would seem appropriate, i.e. cell death.
Response:
We thank the reviewer for this important suggestion. We have re-categorized the cell death phenotypes of cells depleted of the apoptotic regulators. Indeed, the phenotypes were mixed, with some cells still undergoing apoptosis with membrane blebbing and others undergo a new form of death without blebbing. We have separated these two phenotypes in our graphs in all figures. The residual apoptosis seen in Bax/Bak-depleted cells could be due to incomplete depletion or the existence of Bax/Bak-independent apoptotic pathways.
Referee #2:
In this manuscript, Diaz-Martinez et al. investigate Response: We thank the reviewer for the overall positive assessment of our paper. data (e.g., p. 11 "...Bim, had Response: Given the negative nature of the data and existing data on Bim in mitotic cell death, we have removed the statement about Bim, and discussed its role in Discussion. We have included the time lapse data for siNoxa-2 in Figure S3C -D.
Major points Some statements in the main text lack support by
Reference to experimental data is missing on p. 7: "Depletion of p31comet indeed decreased the extent of mitotic adaptation in HeLa cells..." This and the entire following paragraph reports conclusions without reference to data shown in figures.
Response: We thank the reviewer for pointing out this important omission. We have presented data on the terminal phenotypes of HeLa cells with and without siP31-1 by live cell imaging in Figure S2D . The corresponding section has been rewritten accordingly. Fig. 3B, C The screening assay and data analysis should be better explained in the main text.
An indication of experimental variation by error bars should be added to
Response:
As suggested by the reviewer, we have included the screening assay and network analysis as a main figure (Figure 1 ). We have added new sections in the main text explaining the screening procedure, data analysis, and brief descriptions of each functional network. Response: The siRNA screen involved a tremendous amount of work, and in our view, revealed key insights into the cellular responses to antimitotic drugs. In general, we agree with the reviewer that more mechanistic insights are needed to strengthen the paper. Heeding the reviewer's advice, we have worked hard to investigate the mechanisms by which p31 comet suppresses apoptosis and Bax/Bak promote adaptation. As discussed above, we have made significant progress towards understanding the mechanism by which Bax/Bak promote adaptation in U2OS cells. We had initially focused on the mitochondrial factors that were released into the cytosol during apoptosis in a Bax/Bak-dependent manner, including cytochrome C, Smac, Omi, AIF, and Endo G. Inactivation of none of these factors extended mitotic duration. We thus considered a newly established connection between Bax/Bak and the mitochondrial fission factor Drp1. Strikingly, depletion of Drp1 with multiple siRNAs, as well as chemical inhibition of Drp1 with Mdivi-1, lengthened mitotic duration in U2OS cells without altering the extent of apoptosis (Figure 7) . Furthermore, inhibition of protein synthesis or ATP production abrogated the mitotic effects of Drp1 or Bax/Bak inactivation. These results, along with our finding that the APC/C activity is not altered in siBax/Bak cells (Figure 6 ), strongly support a model in which Bax/Bak acts through Drp1 to suppress protein synthesis, thus reducing cyclin B1 steady-state levels and promoting adaptation. Addition of these results has greatly strengthened our paper. We hope that the reviewer now finds our paper suitable for publication. Response: We agree with the reviewer that a role of p31 comet in adaptation has already been established and have included the relevant references in the revision. As pointed out by Reviewer 1, however, the discovery of p31 comet in an unbiased screen argues that it is among the most relevant regulators of life/death decisions during prolonged mitotic arrest. We also wish to point out that our siRNA screen was completed in 2008, and our results on the role of p31 comet in adaptation were obtained in 2009. Due to the inordinate difficulty we encountered in publishing our paper, these results are no longer fresh at this time. Some of the claims of novelty in the original submission were relics from earlier versions of our paper submitted elsewhere. We apologize for not catching these inaccurate claims.
We also agree with the reviewer that a role for Bax/Bak in apoptosis is established, but would like to point out that the main advance of our paper is the discovery of crosstalks between the apoptosis and adaptation pathways.
It is an advance to identify Noxa as being important for mitotic cell death, at least in Hela, but its role may be limited to these cells.
We agree with the reviewer that Noxa is not universally required for mitotic cell death in all cell lines. Due to time constraints, we could not characterize a potential role of Noxa in additional cancer cell lines. However, it would be somewhat surprising if the role of Noxa in mitotic cell death is restricted to HeLa cells.
Where the manuscript is more progressive, for instance indicating that p31comet somehow affects apoptosis in addition to its role in the checkpoint, we unfortunately have no new mechanistic insights. Similarly, whether Noxa, Bak or Bax affect mitotic controls in addition to roles in apoptosis, as is suggested, then we have no information on the mechanism. I think it would be much better for the authors to fully investigate each of these pieces in more detail in order to understand the meaning of the phenomena that they observe; they might then be published separately.
Response: In a separate study in the lab, we have shown that p31 comet regulates growth factor signaling. Its role in suppressing apoptosis is indirectly mediated through this new signal transduction function of p31 comet . That study is almost completed and will be reported in due course. I feel that it is impractical to include those mechanistic studies in the current manuscript. I feel strongly, however, that we should report the initial connection between p31 comet and apoptosis in the current study.
As discussed above, we have presented exciting new data linking the mitochondrial fission factor Drp1in mitotic adaptation. Our results are consistent with a model in which Bax/Bak acts through Drp1 to suppress protein synthesis, thus reducing cyclin B1 steady-state levels and promoting adaptation. Although these new insights are admittedly not yet at a level of mechanistic details that are typical of studies from my lab, they do greatly strength our conclusions in the paper.
The data is deficient in some aspects and lacks statistical analysis; it is not clear how many times experiments were conducted and what variability was found, e.g. the analysis of time in mitosis shown in Fig2F, G and subsequent figures.
Response: We have included averages and standard deviations where appropriate (e.g., Figure 4B , C, G). The number of times each time lapse experiment was repeated is now stated in the main text and figure legends, along with the average and standard deviation of the time differences between key samples. The time differences were calculated as follows. The time at which half of the cells have adapted or died is defined as t 50 for each treatment. The differences between t 50 of different treatments (∆t 50 ) are then averaged over multiple experiments, with the standard deviations shown. This analysis revealed that ∆t 50 was remarkably similar from experiment to experiment. figure 2E, Response: The original figure legend was incorrect. The siCdc20 transfection was performed for 20 hrs, not 48 hrs. By that time, the siCdc20 cells had not accumulated in mitosis. The comparisons of levels were thus informative. We apologize for this error, and have corrected the figure legend.
The experiment shown in
